SCHEMBL13628019

SCHEMBL13628019

COC(=O)Nc1ccc2c(c1)/C(=N/O)C(=O)N2Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 6/20 0.48
CA2 P00918 6/20 0.48
CA12 O43570 5/20 0.48
CA9 Q16790 5/20 0.48
MMP13 P45452 1/20 0.47
ALDH1A1 P00352 6/20 0.44
ALDH2 P05091 3/20 0.44
ALDH3A1 P30838 3/20 0.44
MAPT P10636 4/20 0.44
PKM P14618 1/20 0.44
TSHR P16473 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44
LMNA P02545 2/20 0.42
POLB P06746 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
LRRK2 Q5S007 1/20 0.41
CA4 P22748 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13628025 0.89 MMP13 (0.50) CA1CA2CA12CA9MMP13
SCHEMBL13628015 0.86 MEN1 (0.50) CA1CA2CA12CA9MMP13
SCHEMBL13628027 0.86 MMP13 (0.66) CA1CA2CA12CA9MMP13
SCHEMBL13628054 0.84 CA12 (0.46) CA1CA2CA12CA9MMP13
SCHEMBL13628032 0.84 MMP13 (0.52) CA1CA2CA12CA9MMP13
SCHEMBL13628020 0.83 MEN1 (0.54) CA2CA9ALDH1A1MAPTLMNA
SCHEMBL13628023 0.83 MMP13 (0.49) CA1CA2CA12CA9MMP13
SCHEMBL13628053 0.83 KDM4E (0.53) CA1CA2CA12CA9MMP13
SCHEMBL13628016 0.81 CA12 (0.56) CA1CA2CA12CA9MMP13
SCHEMBL13628029 0.81 KDM4E (0.50) CA1CA2CA12CA9MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 CA1 3628/4885CA2 3142/4885CA12 4791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.